Levy RH - Search Results

1

Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.

Yu J, Petrie ID, Levy RH, Ragueneau-Majlessi I. Yu J, et al. Among authors: levy rh. Drug Metab Dispos. 2019 Feb;47(2):135-144. doi: 10.1124/dmd.118.084905. Epub 2018 Nov 15. Drug Metab Dispos. 2019. PMID: 30442649 Review.

2

New antiepileptic drugs: review on drug interactions.

Hachad H, Ragueneau-Majlessi I, Levy RH. Hachad H, et al. Among authors: levy rh. Ther Drug Monit. 2002 Feb;24(1):91-103. doi: 10.1097/00007691-200202000-00016. Ther Drug Monit. 2002. PMID: 11805729 Review.

3

Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings.

Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. Yu J, et al. Among authors: levy rh. J Pharm Sci. 2017 Sep;106(9):2312-2325. doi: 10.1016/j.xphs.2017.04.004. Epub 2017 Apr 13. J Pharm Sci. 2017. PMID: 28414144

4

Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.

Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. Yu J, et al. Among authors: levy rh. Drug Metab Dispos. 2018 Jun;46(6):835-845. doi: 10.1124/dmd.117.078691. Epub 2018 Mar 23. Drug Metab Dispos. 2018. PMID: 29572333

5

Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3.

McFeely SJ, Ritchie TK, Yu J, Nordmark A, Levy RH, Ragueneau-Majlessi I. McFeely SJ, et al. Among authors: levy rh. Clin Transl Sci. 2019 Jul;12(4):379-387. doi: 10.1111/cts.12623. Epub 2019 Mar 12. Clin Transl Sci. 2019. PMID: 30706983 Free PMC article.

6

Past, Present, and Future of Drug-Drug Interactions.

Levy RH, Ragueneau-Majlessi I. Levy RH, et al. Clin Pharmacol Ther. 2019 Jun;105(6):1286-1288. doi: 10.1002/cpt.1349. Epub 2019 Feb 17. Clin Pharmacol Ther. 2019. PMID: 30773619 Review. No abstract available.

7

Prediction of maximum exposure in poor metabolizers following inhibition of nonpolymorphic pathways.

Collins C, Levy R, Ragueneau-Majlessi I, Hachad H. Collins C, et al. Curr Drug Metab. 2006 Apr;7(3):295-9. doi: 10.2174/138920006776359301. Curr Drug Metab. 2006. PMID: 16611023

8

Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy.

Levy RH, Ragueneau-Majlessi I, Brodie MJ, Smith DF, Shah J, Pan WJ. Levy RH, et al. Ther Drug Monit. 2005 Apr;27(2):193-8. doi: 10.1097/01.ftd.0000153403.99478.1f. Ther Drug Monit. 2005. PMID: 15795651 Clinical Trial.

9

Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.

Ragueneau-Majlessi I, Levy RH, Brodie M, Smith D, Shah J, Grundy JS. Ragueneau-Majlessi I, et al. Among authors: levy rh. Clin Pharmacokinet. 2005;44(5):517-23. doi: 10.2165/00003088-200544050-00005. Clin Pharmacokinet. 2005. PMID: 15871637

10

Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.

Ragueneau-Majlessi I, Boulenc X, Rauch C, Hachad H, Levy RH. Ragueneau-Majlessi I, et al. Among authors: levy rh. Curr Drug Metab. 2007 Dec;8(8):810-4. doi: 10.2174/138920007782798135. Curr Drug Metab. 2007. PMID: 18220561

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

261 results

Search Page

Filters